Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.

3rd Department of Internal Medicine 1st Faculty of Medicine Charles University U Nemocnice 1 CZ 128 21 Praha 2 Prague Czech Republic

Weill Cornell Medical College New York 1305 York Avenue Y 807 New York NY 10021 USA

Zobrazit více v PubMed

Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. doi: 10.1016/S0140-6736(10)61350-5. PubMed DOI PMC

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–483. doi: 10.1016/j.jacl.2013.03.001. PubMed DOI

Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14. doi: 10.1007/s10557-005-5686-z. PubMed DOI

Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103. doi: 10.1161/CIRCULATIONAHA.112.136101. PubMed DOI PMC

Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81. doi: 10.1016/j.jacl.2014.03.002. PubMed DOI

Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71. doi: 10.1016/j.jacl.2014.03.004. PubMed DOI

Cornier MA, Eckel RH. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? Curr Atheroscler Rep. 2015;17(2):475. doi: 10.1007/s11883-014-0475-4. PubMed DOI

Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47–57. doi: 10.1016/j.jacl.2014.02.011. PubMed DOI

Rojas-Fernandez CH, Goldstein LB, Levey AI, Taylor BA, Bittner V, The National Lipid Association's Safety Task Force An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S5–16. doi: 10.1016/j.jacl.2014.02.013. PubMed DOI

Stulc T, Ceska R. Statins, glycemia, and diabetes mellitus: another point of view. Curr Atheroscler Rep. 2014;16(12):458. doi: 10.1007/s11883-014-0458-5. PubMed DOI

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022. doi: 10.1093/eurheartj/ehv043. PubMed DOI PMC

Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29:1553–1568. doi: 10.1016/j.cjca.2013.09.023. PubMed DOI

Pirillo A, Catapano AL. Statin intolerance: diagnosis and remedies. Curr Cardiol Rep. 2015;17(5):582. doi: 10.1007/s11886-015-0582-z. PubMed DOI

Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience. JAMA. 2015;313(10):1011–2. doi: 10.1001/jama.2015.1335. PubMed DOI

Preiss D, Sattar N. Classification of reported statin intolerance. Curr Opin Lipidol. 2015;26(1):65–6. doi: 10.1097/MOL.0000000000000149. PubMed DOI

Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1–23. doi: 10.5114/aoms.2015.49807. PubMed DOI PMC

Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–534. doi: 10.7326/0003-4819-158-7-201304020-00004. PubMed DOI PMC

Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603. doi: 10.1016/j.ahj.2013.06.004. PubMed DOI PMC

Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, et al. Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol. 2014;8(4):401–7. doi: 10.1016/j.jacl.2014.05.005. PubMed DOI

Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses. 2011;77:658–61. doi: 10.1016/j.mehy.2011.07.007. PubMed DOI

Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329–35. doi: 10.1016/j.atherosclerosis.2014.12.016. PubMed DOI PMC

Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34. doi: 10.1016/j.mayocp.2014.08.021. PubMed DOI

Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007;100:554–5. doi: 10.1016/j.amjcard.2007.03.059. PubMed DOI

Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009;103:393–4. doi: 10.1016/j.amjcard.2008.09.095. PubMed DOI

Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101:1747–1748. doi: 10.1016/j.amjcard.2008.02.061. PubMed DOI

Honkanen M. Managing the statin-intolerant patient: low-dose/low-frequency treatment regimens. LipidSpin 2013; 11(4): 9–12. https://www.lipid.org/communications/lipid_spin/lipid-spin-fall-2013. Accessed June 1, 2015

Cannon CP, on behalf of the IMPROVE IT Investigators. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Presented at: American heart Association Scientific Sessions: Late-braking clinical trials: Anti-Lipid Therapy and Prevention of CAD, November 17, 2014. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469598.pdf. Accessed June 1, 2015

Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–84. doi: 10.1016/S0140-6736(10)60656-3. PubMed DOI

HPS2-THRIVE Collaborative Group. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12. doi: 10.1056/NEJMoa1300955. PubMed DOI

AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. doi: 10.1056/NEJMoa1107579. PubMed DOI

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9. doi: 10.1056/NEJMoa1500858. PubMed DOI

Robinson JG et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients. . Presented at: ESC Congress 2014, Hot Line session: Coronary artery disease and lipids, 31 August 2014. http://www.escardio.org/Congresses-&-Events/Congress-resources/ESC-Congress-365/Long-term-safety-tolerability-and-efficacy-of-alirocumab-versus-placebo-in-high.